Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

chron.com - Royalty Pharma: Q2 Earnings Snapshot
Royalty Pharma: Q2 Earnings Snapshot
Chron

NEW YORK (AP) — NEW YORK (AP) — Royalty Pharma (RPRX) on Wednesday reported second-quarter profit of $18 million. On a per-share basis, the New York-based company said it had net income of 3 cents. Earnings, adjusted for non-recurring…

seekingalpha.com - Wolf Report - Royalty Pharma: At The Right P/E, I'm In (But Not Here) (NASDAQ:RPRX)
Royalty Pharma: At The Right P/E, I'm In (But Not Here) (NASDAQ:RPRX)
Seeking Alpha

Royalty Pharma is a market-leading pharmaceutical royalty company with a unique capital allocation model and a 60% industry share. RPRX offers exposure to blockbuster drug revenues with diversified risk but faces concentration in Vertex and lumpy…

afr.com - Michael Smith - Mayne Pharma investors push for break-up after blocked takeover bid
Mayne Pharma investors push for break-up after blocked takeover bid
Australian Financial Review

Mayne Pharma investors are calling for the sale of its women's health and dermatology businesses in the US, after the federal government's decision to block a takeover of the Adelaide-based company last year left them nursing heavy losses. Key…

indianexpress.com - Express News Service - 3 workers killed, 2 injured in chemical leak at Karnataka pharma factory
3 workers killed, 2 injured in chemical leak at Karnataka pharma factory
The Indian Express

2 min read Bengaluru Make us preferred source on Google Three workers were killed and two others were injured after a chemical leak at a pharmaceutical manufacturing unit in the Kadechur-Badiala industrial area of Karnataka's Yadgir district early…

thehindu.com - The Hindu Bureau - Aurobindo Pharma Q1 net rises 25% to ₹1,032 cr; approves merger of three arms
Aurobindo Pharma Q1 net rises 25% to ₹1,032 cr; approves merger of three arms
The Hindu

Generic drugmaker Aurobindo Pharma reported a 25.2% year-on-year (YoY) increase in consolidated net profit to ₹1,032 crore in the June quarter FY27. The higher net profitability came on a 16.3% YoY increase in revenue from operations to…

thehindubusinessline.com - Gland Pharma, Neuland Laboratories team up for sterile API manufacturing
Gland Pharma, Neuland Laboratories team up for sterile API manufacturing
BusinessLine

Gland Pharma and Neuland Laboratories have entered into a long-term a contract development and manufacturing organisation (CDMO) partnership under which Gland will establish a sterile manufacturing suite for active pharmaceutical ingredients (APIs)…

marketbeat.com - Royalty Pharma Q2 Earnings Call Highlights
Royalty Pharma Q2 Earnings Call Highlights
MarketBeat

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks Royalty Pharma NASDAQ: RPRX raised its 2026 outlook for the second consecutive quarter after reporting higher second-quarter royalty receipts, continued capital deployment and progress…

thehindubusinessline.com - Aurobindo Pharma Q1 profit rises 25% as revenue hits record ₹9,150 crore
Aurobindo Pharma Q1 profit rises 25% as revenue hits record ₹9,150 crore
BusinessLine

Aurobindo Pharma's net profit increased 25 per cent at Rs ₹1,032 crore in the first quarter ended June 30, 2026, compared to ₹824 crore in the corresponding quarter of the previous year. The Hyderabad-based company recorded its…

marketbeat.com - NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
MarketBeat

NewAmsterdam Pharma NASDAQ: NAMS used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial preparations ahead of a potential European launch.

marketbeat.com - Urogen Pharma (NASDAQ:URGN) Stock Price Up 9.1% - Here's Why
Urogen Pharma (NASDAQ:URGN) Stock Price Up 9.1% - Here's Why
MarketBeat

Urogen Pharma (NASDAQ:URGN - Get Free Report)'s share price was up 9.1% during mid-day trading on Wednesday. The company traded as high as $43.99 and last traded at $43.56. Approximately 193,743 shares were traded during mid-day trading, a decline…

marketbeat.com - Urogen Pharma (NASDAQ:URGN) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS
Urogen Pharma (NASDAQ:URGN) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS
MarketBeat

Urogen Pharma (NASDAQ:URGN - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02), FiscalAI reports. The…

marketbeat.com - Urogen Pharma Q2 Earnings Call Highlights
Urogen Pharma Q2 Earnings Call Highlights
MarketBeat

3 Bullish Biotech Stocks With Explosive Growth Trends Urogen Pharma NASDAQ: URGN reported second-quarter 2026 revenue of $72.5 million, up from $24.2 million a year earlier, as the commercial launch of bladder cancer treatment ZUSDURI continued to…

marketbeat.com - NewAmsterdam Pharma (NASDAQ:NAMS) Announces Quarterly Earnings Results
NewAmsterdam Pharma (NASDAQ:NAMS) Announces Quarterly Earnings Results
MarketBeat

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.05), FiscalAI reports. NewAmsterdam…

globenewswire.com - ALK Abello - Market launch of the nasal adrenaline spray, neffy, for treatment of adults and children with severe allergies in Canada
Market launch of the nasal adrenaline spray, neffy, for treatment of adults and children with severe allergies in Canada
GlobeNewswire

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced the market launch of neffy2 mg in Canada following the approval by Health Canada in April 2026. The launch of this first ever nasal adrenaline spray for emergency treatment of anaphylaxis…

marketbeat.com - Lazard Asset Management LLC Sells 108,947 Shares of Royalty Pharma PLC $RPRX
Lazard Asset Management LLC Sells 108,947 Shares of Royalty Pharma PLC $RPRX
MarketBeat

Lazard Asset Management LLC cut its position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 81.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,163 shares of…

Receive a Daily briefing on Pharma Industry News

Get Started